These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34991512)

  • 1. Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.
    Álvarez-Torres MDM; Fuster-García E; Juan-Albarracín J; Reynés G; Aparici-Robles F; Ferrer-Lozano J; García-Gómez JM
    BMC Cancer; 2022 Jan; 22(1):40. PubMed ID: 34991512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DSC-PWI presurgical differentiation of grade 4 astrocytoma and glioblastoma in young adults: rCBV percentile analysis across enhancing and non-enhancing regions.
    Pons-Escoda A; Naval-Baudin P; Viveros M; Flores-Casaperalta S; Martinez-Zalacaín I; Plans G; Vidal N; Cos M; Majos C
    Neuroradiology; 2024 Aug; 66(8):1267-1277. PubMed ID: 38834877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular differences between IDH-wildtype glioblastoma and astrocytoma IDH-mutant grade 4 at imaging and transcriptomic levels.
    Álvarez-Torres MDM; López-Cerdán A; Andreu Z; de la Iglesia Vayá M; Fuster-Garcia E; García-García F; García-Gómez JM
    NMR Biomed; 2023 Nov; 36(11):e5004. PubMed ID: 37482922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioma grading using multiparametric MRI: head-to-head comparison among dynamic susceptibility contrast, dynamic contrast-enhancement, diffusion-weighted images, and MR spectroscopy.
    Seo M; Choi Y; Soo Lee Y; Ahn KJ; Kim BS; Park JS; Jeon SS
    Eur J Radiol; 2023 Aug; 165():110888. PubMed ID: 37257338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI.
    Tan W; Xiong J; Huang W; Wu J; Zhan S; Geng D
    J Magn Reson Imaging; 2017 Feb; 45(2):492-499. PubMed ID: 27367599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
    She D; Xing Z; Cao D
    J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
    Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
    J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Yoon BH; Park JS; Kang S; Kwon NJ; Lee KS; Kim CY; Choe G
    Br J Neurosurg; 2023 Oct; 37(5):1233-1236. PubMed ID: 33095064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
    Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH
    Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes.
    Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W
    Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas.
    Röhrich M; Floca R; Loi L; Adeberg S; Windisch P; Giesel FL; Kratochwil C; Flechsig P; Rathke H; Lindner T; Loktev A; Schlemmer HP; Haberkorn U; Paech D
    Eur J Radiol; 2020 Jun; 127():109021. PubMed ID: 32344293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
    Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
    Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M
    Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric MRI and T2/FLAIR mismatch complements the World Health Organization 2021 classification for the diagnosis of IDH-mutant 1p/19q non-co-deleted/ATRX-mutant astrocytoma.
    Sawlani V; Jen JP; Patel M; Jain M; Haq H; Ughratdar I; Wykes V; Nagaraju S; Watts C; Pohl U
    Clin Radiol; 2024 Mar; 79(3):197-204. PubMed ID: 38101998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging.
    Yang X; Xing Z; She D; Lin Y; Zhang H; Su Y; Cao D
    BMC Med Imaging; 2022 May; 22(1):105. PubMed ID: 35644621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma.
    Hu LS; Eschbacher JM; Dueck AC; Heiserman JE; Liu S; Karis JP; Smith KA; Shapiro WR; Pinnaduwage DS; Coons SW; Nakaji P; Debbins J; Feuerstein BG; Baxter LC
    AJNR Am J Neuroradiol; 2012 Jan; 33(1):69-76. PubMed ID: 22095961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
    Sun C; Zhao Y; Shi J; Zhang J; Yuan Y; Gu Y; Zhang F; Gao X; Wang C; Wang Y; Wang Z; Hu P; Qin J; Xiao L; Chang T; Wang L; Xi Y; Yin H; Chen H; Zhang L; Cheng G; Lin J; Zhang M; Li Z; Ye J
    J Neurooncol; 2019 Jun; 143(2):187-196. PubMed ID: 31004262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.
    Latysheva A; Emblem KE; Brandal P; Vik-Mo EO; Pahnke J; Røysland K; Hald JK; Server A
    Neuroradiology; 2019 May; 61(5):545-555. PubMed ID: 30712139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.